Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM

2 de noviembre de 2026 actualizado por: Neurotech Pharmaceuticals

A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2 (MacTel), Including a Randomized Comparative Expansion Cohort

The overall purpose of this global, multicenter, two cohort, central image evaluator masked study is to characterize the clinical safety and efficacy of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane (M-CHFM) for the treatment of MacTel and to evaluate whether its safety profile and efficacy are comparable to those of NT-501 manufactured using the Clinical Hollow Fiber Membrane (CHFM).

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This Phase 3 study consists of two cohorts:

  • Cohort 1 (Extension): Includes participants previously enrolled under the original protocol who received NT-501 (M-CHFM) and will continue follow-up. Participants will undergo evaluations of safety and efficacy from pre-surgery through month 24 or in the event of NT-501 explantation for any reason.
  • Cohort 2 (Expansion): Includes newly enrolled participants randomized 1:1 to receive either NT-501 (M-CHFM) or NT-501 (CHFM). Participants will undergo evaluations of safety and efficacy from pre-surgery through month 12 or in the event of NT-501 explantation for any reason.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • East Melbourne, Australia
      • Perth, Australia
        • Reclutamiento
        • Lion's Eye Institute
        • Contacto:
        • Investigador principal:
          • Ian Constable, MD
      • Sydney, Australia
        • Aún no reclutando
        • Sydney Eye Hospital
        • Contacto:
        • Investigador principal:
          • Elisa Cornish, MD
    • California
      • Walnut Creek, California, Estados Unidos, 94598
        • Activo, no reclutando
        • Bay Area Retina Associates, A Medical Group
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49546
        • Activo, no reclutando
        • Foundation for Vision Research
    • Texas
      • Bellaire, Texas, Estados Unidos, 77401
        • Activo, no reclutando
        • Retina Consultants of Texas

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

To participate in this study, the potential subject and at least 1 of their eyes must meet all of the following criteria:

  1. Subjects must have a positive diagnosis of MacTel with evidence of fluorescein leakage typical of MacTel and at least one of the other features that include hyperpigmentation that is outside of a 500-micron radius from the center of the fovea, retinal opacification, crystalline deposits, right-angle vessels, or inner/outer lamellar cavities seen clinically or on SD-OCT.
  2. Subject must have a break in the ellipsoid zone (EZ) (area of IS/OS loss) as measured by SD-OCT between 0.16 and 2.00 millimeters squared.
  3. Subject's best-corrected visual acuity (BCVA) is 54-letter score or better (20/80 or better) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at screening.
  4. Subject must have steady fixation in the foveal or parafoveal area and sufficiently clear media for good quality retinal imaging.
  5. Subject must be greater than or equal to 21 years of age and less than 80 years of age at screening.
  6. Subject or their legally authorized representative must be able to provide written informed consent to participate in the study, in accordance with the International Conference on Harmonisation Good Clinical Practices guidelines, and local regulations, before initiating any study-related procedures.

Exclusion Criteria

To participate in this study, the potential subject must not meet any of the following criteria. The ocular exclusion criteria are related to the study eye (unless indicated for either eye):

  1. Subject is medically unable to comply with study procedures or follow-up visits.
  2. Subject received intravitreal steroid therapy for non-neovascular MacTel within the last 3 months.
  3. Subject has ever received intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the study eye OR has, within the past 3 months, received intravitreal anti-VEGF therapy in the fellow eye at randomization.
  4. Subject has evidence of ocular disease other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures, or outcome of the study (e.g., uncontrolled glaucoma, severe non-proliferative or proliferative diabetic retinopathy, uveitis).
  5. Subject has a chronic requirement (e.g., ≥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease that, in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted). The exceptions to this exclusion criteria include artificial tears or one glaucoma medication for early or intermediate primary open-angle glaucoma.
  6. Subject has evidence of intraretinal neovascularization or subretinal neovascularization (SRNV), as evidenced by hemorrhage, hard exudate, subretinal fluid or intraretinal fluid in either eye.
  7. Subject has evidence of intraretinal hyperreflectivity by OCT.
  8. Subject has evidence of central serous chorio-retinopathy in either eye.
  9. Subject has evidence of pathologic myopia in either eye.
  10. Subject has significant corneal or media opacities in either eye.
  11. Subject has had a vitrectomy, penetrating keratoplasty, trabeculectomy, or trabeculoplasty.
  12. Subject has any of the following lens opacities: cortical opacity > standard 3, posterior subcapsular opacity > standard 2, or a nuclear opacity > standard 3 as measured on the Age -Related Eye Disease Study (AREDS) clinical lens grading system.
  13. Subject has undergone lens removal in the previous 3 months or YAG laser within 4 weeks.
  14. Previous participation in any Neurotech MacTel clinical trial unless the participant: (1) previously consented and screened for a MacTel study but was a screen failure solely due to insufficient lesion size; or (2) has completed participation in the prior Neurotech MacTel study, is not actively enrolled in another Neurotech MacTel study, and has an eligible study eye that was not the study eye in the previous trial.
  15. Subject was a participant in any other ocular related or ocular impacted clinical trial of an intervention (drug or device) within the last 6 months.
  16. Subject is on chemotherapy.
  17. Subject is pregnant or breastfeeding.
  18. Subject has a history of malignancy that would compromise the 12-month study survival.
  19. Subject with a history of ocular herpes virus in either eye.
  20. Subject has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations, and outcome assessments.
  21. Subject has evidence of subfoveal RPE hyperplasia.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cohort 1 (Extension) - M-CHFM

Previously enrolled Cohort 1 participants received M-CHFM and will undergo evaluations of safety and efficacy from pre-surgery through month 24 or in the event of NT-501 explantation for any reason.

Single implantation of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane (M-CHFM)

Experimental: Cohort 2 (Expansion) - M-CHFM

Participants are randomized 1:1 to receive M-CHFM. Participants will undergo evaluations of safety and efficacy from pre-surgery through month 12 or in the event of NT-501 explantation for any reason.

Single implantation of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane (M-CHFM)

Comparador activo: Cohort 2 (Expansion) - CHFM

Participants are randomized 1:1 to receive CHFM (US commercially available ENCELTO). Participants will undergo evaluations of safety and efficacy from pre-surgery through month 12 or in the event of NT-501 explantation for any reason.

Single implantation of NT-501 manufactured using the Clinical Hollow Fiber Membrane (CHFM)

Otros nombres:
  • Encelacado

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cohort 1 (Extension) - Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography
Periodo de tiempo: Baseline to 24 months

Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye of NT-501 in participants who received NT-501 with M-CHFM

Baseline to 24 months
Cohort 2 (Expansion) - Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography
Periodo de tiempo: Baseline to 12 months

Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye of NT-501 in participants who received NT-501 with M-CHFM as compared to NT-501 with CHFM

Baseline to 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cohort 1 (Extension) - Incidence of ocular and non-ocular adverse events
Periodo de tiempo: Baseline to 24 months

Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs)

Baseline to 24 months
Cohort 2 (Expansion) - Incidence of ocular and non-ocular adverse events
Periodo de tiempo: Baseline to 12 months

Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs)

Baseline to 12 months
Cohort 1 (Extension) - Percentage of participants with a loss of 15 letters or more in best-corrected visual acuity
Periodo de tiempo: Baseline to 24 months

Percentage of participants with a loss of 15 letters or more in best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chart

Baseline to 24 months
Cohort 2 (Expansion) - Percentage of participants with a loss of 15 letters or more in best-corrected visual acuity
Periodo de tiempo: Baseline to 12 months

Percentage of participants with a loss of 15 letters or more in best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chart

Baseline to 12 months

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Cohort 1 (Extension) - Aqueous CNTF Presence
Periodo de tiempo: Month 12 - Month 24

Either a binary result (present/absent) for measurable CNTF or actual CNTF concentration

Month 12 - Month 24
Cohort 2 (Expansion) - Aqueous CNTF Presence
Periodo de tiempo: Baseline to 12 months

Either a binary result (present/absent) for measurable CNTF or actual CNTF concentration

Baseline to 12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Thomas Aaberg, Jr., MD, Neurotech Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de marzo de 2025

Finalización primaria (Estimado)

1 de mayo de 2028

Finalización del estudio (Estimado)

24 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

29 de abril de 2024

Primero enviado que cumplió con los criterios de control de calidad

29 de abril de 2024

Publicado por primera vez (Actual)

2 de mayo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NTMT-03C

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .